BI’s Olodaterol Wants Novel Exercise Claims In COPD
This article was originally published in The Pink Sheet Daily
Executive Summary
Proposed claims for Striverdi Respimat include improved exercise tolerance and increased inspiratory capacity, but FDA has no clear regulatory pathway for them.